X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.
Lead Product(s): rhGAD65,Vitamin D3
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2024
Details:
Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel®. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.
Lead Product(s): rhGAD65,Vitamin D3
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
The partnership aims to identify participants for the DiaPrecise trial, an open-label trial evaluating the safety, feasibility and immune response of intralymphatic injections of Diamyd (recombinant human glutamic acid decarboxylase) in children at risk of type 1 diabetes.
Lead Product(s): Recombinant Human Glutamic Acid Decarboxylase
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: DiaUnion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 07, 2023
Details:
Diamyd® is an antigen-specific immunotherapy for the treatment of autoimmune diabetes. Diamyd® is based on the protein GAD65, an endogenous antigen involved in the pathology of autoimmune diabetes.
Lead Product(s): Recombinant Human Glutamic Acid Decarboxylase
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
The collaboration aims to support Diamyd Medical's ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd (recombinant human glutamic acid decarboxylase), an antigen-specific immunotherapy for the preservation of endogenous insulin production.
Lead Product(s): Recombinant Human Glutamic Acid Decarboxylase
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: JDRF
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration April 04, 2023
Details:
Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in Company's European Phase IIb trial.
Lead Product(s): GAD65-Alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2022
Details:
The diabetes vaccine Diamyd® (GAD-alum) is an antigen-specific immunotherapy for the preservation of endogenous insulin production. The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA.
Lead Product(s): GAD65-Alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
Primary endpoints of safety and tolerability were met in Phase II clinical trial GADinLADA, in which diabetes vaccine Diamyd (GAD-alum) was administered directly into lymph node of 14 patients aged 30 to 70 years with autoimmune form of diabetes called LADA.
Lead Product(s): GAD-alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. The Phase III trial DIAGNODE-3, with a planned start date later during 2021 and primary completion end of 2025.
Lead Product(s): rhGAD65,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
The results support a precision medicine approach with Diamyd® where significant effect on the preservation of endogenous insulin producing capacity and improved blood glucose control was seen in individuals that carry a specific genotyp, HLA DR3-DQ2.
Lead Product(s): GAD-alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
